Chengdu Origen and Vanotech have dosed the first patient in their VAN-2401 Phase 1 trial evaluating KH658, a gene therapy administered via a single suprachoroidal injection for wet AMD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.